Welcome to our dedicated page for Odyssey Health news (Ticker: ODYY), a resource for investors and traders seeking the latest updates and insights on Odyssey Health stock.
Odyssey Health Inc. (OTCQB: ODYY) is a medical company focused on life-saving and life-enhancing medical solutions, and its news flow reflects this emphasis on critical care and diagnostic technologies. Company announcements highlight development milestones, licensing transactions, financing arrangements and strategic asset sales that shape its evolving portfolio.
Recent news has detailed Odyssey’s entry into the breast cancer diagnostics marketplace through a Master Technology and Sub-license Agreement for exclusive, worldwide rights to BreastCheck ae, a non-invasive test for breast abnormalities. Press releases describe BreastCheck ae as a home-use, temperature-based screening tool that provides results in about 15 minutes and is intended to complement established diagnostic procedures. Updates also cover regulatory status, including FDA registration in the United States and registrations with authorities in the European Union and the United Kingdom.
Odyssey’s news archive also covers progress on its Save A Life choking rescue device, a patented vacuum-based system designed to dislodge airway obstructions rapidly. The company has reported creating a prototype and planning further development with the goal of an FDA submission, illustrating how it communicates development stages and regulatory intentions to investors and stakeholders.
Another key theme in Odyssey’s news is corporate and financial strategy. Releases describe the sale of its neurological drug technology pipeline, including the concussion candidate ONP-002, to Oragenics, Inc., as well as the resulting investment in Oragenics preferred stock. Additional coverage explains long-term service contracts and financing facilities, such as the multi-year maintenance service agreement and related funding capacity with Mast Hill Fund, L.P., which the company characterizes as supporting its transition toward recurring revenue and commercialization initiatives.
Investors and observers can use the ODYY news page on Stock Titan to follow these developments, including device development updates, licensing agreements, regulatory steps, financing transactions and portfolio changes that may influence Odyssey Health’s business trajectory.
Odyssey Health (OTCQB: ODYY) announced a multi-million-dollar, nine-year maintenance service contract for a commercial medical property, which the company says will create a stable, recurring revenue stream and support its transition to cash-generating operations.
The company also secured a financing facility of up to $25 million; an initial tranche of $500,000 will be used to advance Odyssey’s BreastCheck® sub-licensing program for a rapid, non-invasive breast screening test. Management described the deals as improving financial flexibility and enabling strategic commercialization initiatives.
Odyssey Health (OTCQB: ODYY) announced on October 16, 2025 that its subsidiary Odyssey Medical Devices signed a sub-licensing agreement for exclusive worldwide marketing and distribution rights to BreastCheck®, a non-invasive, at-home breast screening test with 15-minute results. The agreement is subject to closing conditions.
BreastCheck® is described as a first-line screening tool (not a mammogram replacement) and the technology is FDA registered in the United States and registered with relevant authorities in the European Union and the United Kingdom. Management expects near-term commercialization and initial revenue, signalling a move from development-stage to revenue-generating medtech.
Odyssey Health (OTCQB: ODYY) has announced plans to advance the development of its patented Save A Life (SAL) choking rescue device, targeting an FDA submission in 2026. The device is designed as a vacuum-based solution for removing lodged objects from a choking victim's throat.
The SAL device features a vacuum chamber with a replaceable mouthpiece that can be quickly deployed in emergencies. When activated, it creates an appropriate vacuum force to dislodge throat obstructions without causing trauma to the victim. The company highlights the significant market need, citing 5,000 annual choking deaths in the US and over 100,000 yearly emergency room visits related to choking incidents.
FAQ
What is the current stock price of Odyssey Health (ODYY)?
What is the market cap of Odyssey Health (ODYY)?
